# LUMICKS Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lumicks-technologies-b-v

- Industry: Biotechnology
- Headquarters: Amsterdam, Netherlands
- Website: www.lumicks.com
- Total disclosed funding: $93M
- Latest round: Series D (Apr 16, 2021)
- Investors on record: 8

## About

LUMICKS Technologies, based in the Netherlands, specializes in advanced technologies for biomolecular and cellular research, delivering innovative solutions that enhance understanding of molecular interactions and therapeutic mechanisms.Founded in 2014, LUMICKS Technologies B.V. is focused on providing scientific instruments for academic and pharmaceutical research. The company has conducted a total of 3 deals, with its most recent funding round, Series D, taking place on October 11, 2024, raising EUR 77.60 mn from investors including Farallon Capital Management and T. Rowe Price. The CEO is Olivier Heyning and the founder is Erwin Peterman.LUMICKS offers advanced technologies primarily designed for academic and pharmaceutical research, focusing on biomolecular mechanisms and cellular interactions. Their core products include Cell Avidity, which quantifies binding strength between cells and proteins, and Dynamic Single-Molecule solutions for real-time observation of molecular interactions. These products serve a global clientele, including universities and pharmaceutical companies, with significant demand in North America, Europe, and parts of Asia.In the most recent fiscal year of 2022, LUMICKS reported revenue of EUR 18,878,807.20 and an EBITDA of EUR -32,684,626.60. The company's revenue is generated through sales of research instruments and services, primarily under a B2B model with academic institutions and pharmaceutical firms.In October 2024, LUMICKS Technologies B.V. secured EUR 20 million in venture debt from the European Investment Bank. This funding will expedite the development and launch of their advanced cell avidity platform aimed at cancer immunotherapy research. The company plans to expand its offerings and may target new markets in North America and Asia by 2025, enhancing their product portfolio to better serve the growing needs in these regions.

## Funding rounds

- Series D, Apr 16, 2021, $93M — T Rowe Price, Gilde Healthcare, Pura Vida Investments, Farallon Capital Management, SB Investment Advisers, Parian Global Management, Irving Investors, Lauxera Capital Partners
- Series A, Jan 1, 2017 — Gilde Healthcare

## Investors

- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series D
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series D
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series D
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series D
- Parian Global Management (https://capitalatlas.ai/funds/parian-global-management) — Series D
- Irving Investors (https://capitalatlas.ai/funds/irving-investors) — Series D
- Lauxera Capital Partners (https://capitalatlas.ai/funds/lauxera-capital-partners) — Series D